Skip to main content

FY2024 Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Operating Results Summary

  • Net sales

    64,139 million yen

    YOY 2.1%

  • Operating profit

    5,331 million yen

    YOY (18.0)%

  • Ordinary profit

    5,107 million yen

    YOY (21.7)%

  • Profit attributable to owners of parent

    5,101 million yen

    YOY (32.4)%

  • Earnings per share

    179.95 yen

    YOY (32.5)%

The Group’s net sales in the consolidated fiscal year under review were 64,139 million yen, up 1,296 million yen year on year (YoY). This was mainly due to an increase in sales in the pharmaceutical business, which saw strong sales of products in the obstetrics and gynecology field, and an increase in sales in the animal health business, which saw growth in the feed additive product line. Cost of sales was 32,803 million yen, and cost of sales ratio was down 0.1% YoY, resulting in an increase of 670 million yen in gross profit YoY to 31,335 million yen. At the same time, selling, general and administrative expenses increased by 1,839 million yen YoY to 26,003 million yen owing to the impact of increased expenses for the progress in research and development. As a result, operating profit decreased by 1,168 million yen YoY to 5,331 million yen. Ordinary profit was 5,107 million yen, after recording 398 million yen in non-operating income and 622 million yen in non-operating expenses. Profit attributable to owners of parent in the consolidated fiscal year under review was 5,101 million yen due to extraordinary gains of 127 million yen on the sale of investment securities, gains of 1,257 million yen from subsidiary-related profit and loss of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company that was an equity method affiliate, along with consolidation as a consolidated subsidiary, and extraordinary losses of 300 million yen on the impairment of intangible assets. Compared to the same period of the previous fiscal year, Profit attributable to owners of parent decreased by 2,444 million yen owing to a reaction to the recording of extraordinary gains from the sale of investment securities.

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 14,493 28,617 44,055 56,655
Animal health business 1,800 3,640 5,703 7,246
Other businesses 57 113 166 237

(i) Pharmaceutical business

The pharmaceutical business, which focuses on the three fields: internal medicine, obstetrics and gynecology, and urology, showed favorable trends overall, despite the impact of the NHI drug price revisions. A look at results by product shows that the results in the field of obstetrics and gynecology were driven by the large-scale growth in the uterine fibroid and endometriosis agent RELUMINA (relugolix), to 10,531 million yen (up 6.3% YoY), and the dysmenorrhea agent DroEthi (drospirenone/ ethinylestradiol), which went on sale in June 2022, largely drove performance with sales of 7,502 million yen (up 22.5% YoY). Sales also grew in the internal medicine area, as sales of the thyroid hormone agent THYRADIN (levothyroxine), our main product in this field, grew to 8,113 million yen (up 3.2% YoY) and those of the poorly absorbable rifamycin antimicrobial agent RIFXIMA (rifaximin) to 6,455 million yen (up 10.1% YoY). In the urology field, sales of the LH-RH derivative microcapsule sustained-release agent LEUPRORELIN (leuprorelin) were 4,003 million yen (down 9.6% YoY).

As a result of the above factors, the segment sales were 56,655 million yen (up 1.1% YoY), and segment profit was 6,349 million yen (down 17.0% YoY).

(ii) Animal health business

Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives, were 7,246 million yen (up 8.7% YoY), and the segment profit was 300 million yen (up 53.7% YoY) because feed additives and other products turned to an increase in earnings and sales of veterinary pharmaceuticals increased.

(iii) Other businesses

Sales of other businesses, which include clinical testing, medical devices, were 237 million yen (up 45.8% YoY). Segment profit was 2 million yen (vs. a loss of 125 million yen in the same period of the previous year).

Financial Position

Financial Position Summary

  • Total assets

    100,534 million yen

    YOY 10.8%

  • Net assets

    69,195 million yen

    YOY 11.7%

  • Equity ratio

    65.0 %

    YOY (3.2)point

Overview of Financial Position

(Assets)

Total assets at the end of the consolidated fiscal year under review stood at 100,534 million yen, up 9,789 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to increases in construction in progress and goodwill despite decreases investment securities, and cash and deposits.

(Liabilities)

Total liabilities at the end of the consolidated fiscal year under review stood at 31,339 million yen, up 2,523 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to decreases in income taxes payable despite increases in accounts payable - trade and short-term borrowings.

(Net assets)

Total assets at the end of the consolidated fiscal year under review stood at 69,195 million yen, up 7,265 million yen from the end of the consolidated fiscal previous year. This figure was due primarily to an increase in retained earnings resulting from the recording of non-controlling interests and profit attributable to owners of parent.

The equity ratio was 65.0%, down 3.2 percentage points from the end of the previous consolidated fiscal year.

Cash Flow Summary

  • Cash flows from operating activities

    2,485 million yen

  • Cash flows from investing activities

    (6,124) million yen

  • Cash flows from financing activities

    (2,956) million yen

  • Cash and cash equivalents at end of period

    10,603 million yen

Overview of Cash Flow Position

The balance of cash and cash equivalents at the end of the current consolidated fiscal year stood at 10,603 million yen, down 6,135 million yen from the end of the previous consolidated fiscal year.

The standing of each type of cash flow for the current fiscal year, and major contributing factors of each, are summarized below.

(Cash flows from operating activities)

Net cash provided by operating activities was 2,485 million yen (vs. a gain of 1,486 million yen in the same period of the previous year), due mainly to the recording of profit before income taxes, despite a decrease in amount of income taxes.

(Cash flows from investing activities)

Net cash used in investing activities was 6,124 million yen (vs. a gain of 1,706 million yen in the same period of the previous year). This was due mainly to a gain of property, plant and equipment.

(Cash flows from financing activities)

Net cash used in financing activities was 2,956 million yen (vs. a loss of 3,943 million yen in the same period of the previous year). This was due mainly to repayments of long-term borrowings.